Affiliations
Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
Department of Materials Science and Engineering, Sharif University of Technology, PO Box 11365-9466, 14588 Tehran, Iran
Advanced Nanobiotechnology & Nanomedicine research group (ANNRG), Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA
Harvard MIT Division of Health Science and Technology, Cambridge, MA 02139, USA
* These three authors contributed equally to this book.
About the authors
Mahdi Karimi received his BSc in Medical Laboratory Science from the Iran
University of Medical Science (IUMS), in 2005. In 2008, he gained his MSc in
Medical Biotechnology from Tabriz University of Medical Science and joined the
Tarbiat Modares University as a PhD student in the field of nanobiotechnology.
He completed his research in 2013.
During his research, in 2012, he affiliated with the laboratory of Professor
Michael Hamblin in the Wellman Center for Photomedicine at Massachusetts General
Hospital and Harvard Medical School as a researcher visitor, where he
contributed to the design and construction of new smart nano-particles for
drug/gene delivery. On completion of this study, he joined, as Assistant
Professor, the Department of Medical Nanotechnology at IUMS. His current
research interests include the design of smart nanoparticles in drug/gene
delivery and microfluidic systems. He has established a scientific collaboration
between his lab and Professor Michael Hamblin's lab to design new classes of
smart nanovehicles in drug/gene delivery systems.
Parham Sahandi Zangabad graduated with a BSc from Sahand University of Technology
(SUT), Tabriz, Iran, in 2011. He received his MSc in
Nanomaterials/Nanotechnology from Sharif University of Technology (SUT), Tehran,
Iran. Concurrently, he became the research assistant at the Research Center for
Nanostructured and Advanced Materials (RCNAM), SUT, Tehran, Iran. As a BSc and
then MSc student he worked on the assessment of microstructural/mechanical
properties of friction stir welded pure copper and friction stir processed
hybrid TiO2–Al3Ti–MgO/Al nanocomposites. Furthermore, he has done several
experiments on synthesis and characterization of sol–gel fabricated ceramic
nanocomposite particles.
The advent of innovative nanomaterials and nanotechnology interested him in
interfacial sciences/technologies and also nanomedicine, including
nanoparticle-based drug delivery systems and nanobiosensors.
He has now joined Professor Karimi's Nanobiotechnology Research lab in the Iran
University of Medical Science, Tehran, Iran, in association with Professor
Hamblin from Harvard Medical School, Boston, USA; working on smart
micro/nanocarriers applied in therapeutic agent delivery systems employed for
diagnosis and therapy of various diseases and disorders such as cancers and
malignancies, inflammations, infections, etc.
Amir Ghasemi did his BSc at Sharif University of Technology (SUT), the most
prestigious technical university in Iran. He joined the polymeric materials
research group in 2012, and received his MSc in Materials Engineering from SUT.
For his MSc project, he worked on thermoplastic starch (TPS)/cellulose
nanofibers (CNF) biocomposites, under the supervision of Professor Bagheri. He
synthesized a fully biodegradable nanocomposite, and evaluated the effects of
CNF on mechanical and biodegradation of TPS.
His research interests lie in the area of mechanical properties of biopolymers
and polymer composites, ranging from material design to the performance of the
final product. He also works on micro/nano materials, and bio-based polymers as
drug carriers under the supervision of Professor Karimi and Professor Hamblin
from the Harvard Medical School.
He now works at Parsa Polymer Sharif, involved in thermoplastics compounding. He
would like to thank Professor Karimi and Professor Hamblin for the opportunity
to contribute to this work and most importantly learn about such drug delivery
systems.
Michael R Hamblin PhD is a principal investigator at the Wellman Center for
Photomedicine, Massachusetts General Hospital, an associate professor of
dermatology, Harvard Medical School and the affiliated faculty of Harvard–MIT
Division of Health Science and Technology. He directs a laboratory of around 12
scientists who work in photodynamic therapy and low-level light therapy. He has
published 274 peer-reviewed articles, is associate editor or eight journals and
serves on NIH study sections. He has edited ten proceedings volumes, together
with four other major textbooks on PDT and photomedicine. In 2011 Dr Hamblin was
honored by election as a Fellow of SPIE.
